CARPL.ai

CARPL.ai is a radiology AI platform that helps hospitals and imaging groups test, deploy and monitor third-party clinical AI apps from a single, vendor-neutral workspace. It sits between PACS, RIS and AI vendors, routing studies and returning results to radiologists. The platform is FDA-cleared and CE-marked. Pricing is enterprise-only and quoted on request after a short demo call.

What is CARPL.ai?

CARPL.ai is a vendor-neutral platform for bringing radiology AI into clinical use. A provider connects it once, then picks apps from its marketplace. It handles study routing, result delivery, validation and monitoring.

The company grew out of the CARING research group linked to Mahajan Imaging in New Delhi, with Vidur Mahajan as CEO. It gained FDA 510(k) clearance in 2024 and a CE mark later. In July 2026 it reported a US$10 million Series A led by IFC.

Key Features

  • AI marketplace: CARPL.ai lists more than 300 radiology AI applications from over 100 vendors, according to its website. Apps cover all body parts, modalities and disease groups, while CB Insights quotes an older 250-app figure.
  • Single integration: CARPL.ai connects once to PACS and RIS, then serves every app through that link. Hospitals avoid a separate integration project for each AI vendor they add.
  • Validation tools: Teams test candidate algorithms on local studies before purchase. Single-click performance reports show confusion matrices, AUC-ROC curves and false positive or false negative examples, giving clinical leads hard evidence for purchase decisions.
  • Performance monitoring: Monitoring tracks deployed models after go-live to catch drift early. Radiology leaders can spot weaker results on particular scanners or patient groups and retire apps that underperform.
  • Workflow orchestration: CARPL.ai routes chosen studies to the right apps and returns findings to radiologists. Routing rules decide which exams go to which algorithm, so results arrive without manual uploads.
  • Universal viewer: A built-in viewer displays many AI output types, including probability scores, ROI coordinates, structured reports, GSPS DICOM and segmentations. Radiologists review results from different vendors in one consistent format.
  • Flexible hosting: The platform runs with any cloud provider or on hospital servers. On-premise deployment helps organisations with strict data residency or security rules keep imaging studies inside their own network.
  • Partner integrations: CARPL.ai lists integrations with Philips, Fujifilm, DeepHealth, Agfa, Intelerad, RamSoft, Paxera Health and Adva PACS. PACS and RIS vendors can offer the marketplace inside their own systems.

Pros

  • Vendor neutral: Hospitals can mix algorithms from different developers on one platform. CB Insights contrasts this marketplace model with single-platform rivals such as deepc, and switching vendors does not mean rebuilding the integration.
  • Regulatory clearance: CARPL.ai holds FDA 510(k) clearance and a CE mark, and CB Insights also lists ANVISA, TGA and HSA clearances. That breadth reassures procurement teams in several regions.
  • Less IT effort: One integration replaces many separate vendor projects. CARPL.ai describes a single interface, data channel and procurement channel for testing, deploying and monitoring AI, which lightens the load on hospital IT.
  • Evidence before purchase: Local testing shows how an algorithm performs on your own scanners and patients before you buy. That matters because AI accuracy often varies between sites.
  • Established customers: The website lists organisations such as Stanford AIMI, Royal Marsden, RadNet, SingHealth and AIIMS. These references give buyers peers to consult during due diligence, from academic centres to large imaging chains.

Cons

  • No public pricing: CARPL.ai sells through quotes after a demo, and directories list no figures. Early budgeting is hard, so ask for platform, hosting and support costs together.
  • Enterprise focus: The platform suits hospitals, imaging chains and teleradiology groups, not individual clinicians. Onboarding is guided rather than self-service, so small practices may find it heavy.
  • App costs extra: Most marketplace algorithms carry separate vendor licence fees. The total cost grows with each app you add on top of the platform licence, so a broad AI programme needs a realistic multi-year budget.
  • Setup still needed: Local integration with PACS and RIS needs IT coordination and agreed hosting. Expect a project timeline with hosting decisions, routing rules and testing, rather than a same-day start.
  • App clearance varies: Platform clearance does not cover every third-party algorithm. Each app still needs its own regulatory approval for clinical use in your country, which buyers must check separately before deployment.

Who is Using CARPL.ai?

  • Hospital radiology departments: Running several AI tools in one workflow.
  • Teleradiology and imaging chains: Keeping AI routing consistent across sites.
  • PACS and RIS vendors: Adding an AI marketplace through partnerships.
  • AI developers and researchers: Distributing and monitoring their models.

Pricing

CARPL.ai does not publish prices and sells through quotes after a demo (checked October 2026).

Plan Price What you get
Platform licence Contact for pricing Marketplace, integration and monitoring
Marketplace apps Set per vendor Individual algorithm licences
Validation and research use Contact for pricing Local model testing

Directories list no public figures either. Confirm app fees and hosting costs with sales before you budget.

What Makes CARPL.ai Unique?

One hospital connection opens many algorithms plus tools to test and watch them. Most vendors sell a single model. CARPL.ai pairs a broad marketplace with local validation and monitoring, which matters because AI accuracy often varies between sites, scanners and patient groups. Few rivals combine all three under one cleared platform.

Compatibilities and Integrations

  • Imaging systems: Works with PACS and RIS via DICOM.
  • Partner platforms: Reported partners include RamSoft.
  • Deployment: Cloud or hospital servers.
  • Results output: Findings return to the usual viewer.

CARPL.ai Tutorials

Onboarding is guided, not self-service.

  1. Book a demo and share your PACS set-up.
  2. Agree hosting and connect PACS and RIS.
  3. Pick apps and validate them locally.
  4. Set routing rules for chosen studies.
  5. Review monitoring and retire weak apps.

How We Rated It

Criterion Score Why
Accuracy and Reliability 4.3 Validation and monitoring built in
Ease of Use 3.6 Needs IT setup and training
Functionality and Features 4.6 Broad marketplace plus orchestration
Performance and Speed 4.1 Automated routing reduces delays
Customization and Flexibility 4.2 Cloud or on-premise options
Data Privacy and Security 4.3 Regulatory clearances and local hosting
Support and Resources 3.8 Enterprise onboarding, limited public docs
Cost-Efficiency 3.2 No public prices, app fees extra
Integration Capabilities 4.6 Single PACS and RIS connection
Overall Score 4.1 Average of the nine criteria

Summary

CARPL.ai suits hospitals and imaging groups wanting several AI tools without separate integrations. Its main limitation is opaque pricing, with extra licence fees for most marketplace apps. We rate it highly for integration depth and built-in validation. Before signing, ask for a validation pilot on your own studies.

FAQ

Frequently Asked Questions

Find answers to the most common questions about our services, reviews, tools, platforms, and more.

CARPL.ai is used to deploy, test and monitor radiology AI apps inside hospital workflows. It connects once to PACS and RIS, routes studies to chosen algorithms, and sends results back to radiologists, saving IT teams from building separate integrations for every AI vendor.

CARPL.ai does not publish prices. It sells enterprise licences quoted after a demo, and individual marketplace apps usually carry their own vendor fees. Ask about hosting, support and validation costs together so your total budget reflects the full set-up in October 2026.

Yes. CARPL.ai reported US FDA 510(k) clearance for its platform in 2024 and later announced a CE mark in Europe. Clearance covers the platform layer, so each third-party algorithm still needs its own regulatory approval for clinical use.

CARPL.ai is led by CEO Vidur Mahajan and grew out of the CARING research group connected to Mahajan Imaging in New Delhi. The company has since raised venture funding, including a reported US$10 million Series A led by IFC in 2026.

Yes. CARPL.ai supports both cloud and on-premise deployment, which helps hospitals with strict data residency or security rules. The right option depends on your IT policies, study volumes and how many AI applications you plan to run through the platform.

No. CARPL.ai mainly acts as a vendor-neutral platform and marketplace for third-party radiology algorithms. Its own value lies in integration, routing, validation and monitoring, so you can combine models from different developers within one consistent clinical workflow.

CARPL.ai lets teams run candidate algorithms on local studies and compare outputs against reference reads before purchase. After go-live, monitoring tools track performance over time, helping radiology leaders spot drift, false positives or weaker results on particular scanners or patient groups.

Hospitals comparing radiology AI platforms often look at Aidoc's aiOS, Blackford Analysis, deepc's deepcOS and the Nuance Precision Imaging Network. Each offers a marketplace or orchestration layer, so compare app catalogues, PACS compatibility, validation tools and pricing models before choosing.

CARPL.ai is used to deploy, test and monitor radiology AI apps inside hospital workflows. It connects once to PACS and RIS, routes studies to chosen algorithms, and sends results back to radiologists, saving IT teams from building separate integrations for every AI vendor.

CARPL.ai does not publish prices. It sells enterprise licences quoted after a demo, and individual marketplace apps usually carry their own vendor fees. Ask about hosting, support and validation costs together so your total budget reflects the full set-up in October 2026.

Yes. CARPL.ai reported US FDA 510(k) clearance for its platform in 2024 and later announced a CE mark in Europe. Clearance covers the platform layer, so each third-party algorithm still needs its own regulatory approval for clinical use.

CARPL.ai is led by CEO Vidur Mahajan and grew out of the CARING research group connected to Mahajan Imaging in New Delhi. The company has since raised venture funding, including a reported US$10 million Series A led by IFC in 2026.

Yes. CARPL.ai supports both cloud and on-premise deployment, which helps hospitals with strict data residency or security rules. The right option depends on your IT policies, study volumes and how many AI applications you plan to run through the platform.

No. CARPL.ai mainly acts as a vendor-neutral platform and marketplace for third-party radiology algorithms. Its own value lies in integration, routing, validation and monitoring, so you can combine models from different developers within one consistent clinical workflow.

CARPL.ai lets teams run candidate algorithms on local studies and compare outputs against reference reads before purchase. After go-live, monitoring tools track performance over time, helping radiology leaders spot drift, false positives or weaker results on particular scanners or patient groups.

Hospitals comparing radiology AI platforms often look at Aidoc's aiOS, Blackford Analysis, deepc's deepcOS and the Nuance Precision Imaging Network. Each offers a marketplace or orchestration layer, so compare app catalogues, PACS compatibility, validation tools and pricing models before choosing.

CARPL.ai is used to deploy, test and monitor radiology AI apps inside hospital workflows. It connects once to PACS and RIS, routes studies to chosen algorithms, and sends results back to radiologists, saving IT teams from building separate integrations for every AI vendor.

CARPL.ai does not publish prices. It sells enterprise licences quoted after a demo, and individual marketplace apps usually carry their own vendor fees. Ask about hosting, support and validation costs together so your total budget reflects the full set-up in October 2026.

Yes. CARPL.ai reported US FDA 510(k) clearance for its platform in 2024 and later announced a CE mark in Europe. Clearance covers the platform layer, so each third-party algorithm still needs its own regulatory approval for clinical use.

CARPL.ai is led by CEO Vidur Mahajan and grew out of the CARING research group connected to Mahajan Imaging in New Delhi. The company has since raised venture funding, including a reported US$10 million Series A led by IFC in 2026.

Yes. CARPL.ai supports both cloud and on-premise deployment, which helps hospitals with strict data residency or security rules. The right option depends on your IT policies, study volumes and how many AI applications you plan to run through the platform.

No. CARPL.ai mainly acts as a vendor-neutral platform and marketplace for third-party radiology algorithms. Its own value lies in integration, routing, validation and monitoring, so you can combine models from different developers within one consistent clinical workflow.

CARPL.ai lets teams run candidate algorithms on local studies and compare outputs against reference reads before purchase. After go-live, monitoring tools track performance over time, helping radiology leaders spot drift, false positives or weaker results on particular scanners or patient groups.

Hospitals comparing radiology AI platforms often look at Aidoc's aiOS, Blackford Analysis, deepc's deepcOS and the Nuance Precision Imaging Network. Each offers a marketplace or orchestration layer, so compare app catalogues, PACS compatibility, validation tools and pricing models before choosing.

CARPL.ai is used to deploy, test and monitor radiology AI apps inside hospital workflows. It connects once to PACS and RIS, routes studies to chosen algorithms, and sends results back to radiologists, saving IT teams from building separate integrations for every AI vendor.

CARPL.ai does not publish prices. It sells enterprise licences quoted after a demo, and individual marketplace apps usually carry their own vendor fees. Ask about hosting, support and validation costs together so your total budget reflects the full set-up in October 2026.

Yes. CARPL.ai reported US FDA 510(k) clearance for its platform in 2024 and later announced a CE mark in Europe. Clearance covers the platform layer, so each third-party algorithm still needs its own regulatory approval for clinical use.

CARPL.ai is led by CEO Vidur Mahajan and grew out of the CARING research group connected to Mahajan Imaging in New Delhi. The company has since raised venture funding, including a reported US$10 million Series A led by IFC in 2026.

Yes. CARPL.ai supports both cloud and on-premise deployment, which helps hospitals with strict data residency or security rules. The right option depends on your IT policies, study volumes and how many AI applications you plan to run through the platform.

No. CARPL.ai mainly acts as a vendor-neutral platform and marketplace for third-party radiology algorithms. Its own value lies in integration, routing, validation and monitoring, so you can combine models from different developers within one consistent clinical workflow.

CARPL.ai lets teams run candidate algorithms on local studies and compare outputs against reference reads before purchase. After go-live, monitoring tools track performance over time, helping radiology leaders spot drift, false positives or weaker results on particular scanners or patient groups.

Hospitals comparing radiology AI platforms often look at Aidoc's aiOS, Blackford Analysis, deepc's deepcOS and the Nuance Precision Imaging Network. Each offers a marketplace or orchestration layer, so compare app catalogues, PACS compatibility, validation tools and pricing models before choosing.

Reviews (0)

Write a Review

Write a Review

Your email address will not be published. Required fields are marked *

Your rating *
Select a rating